Core Insights - VivoSim Labs, Inc. has appointed Dr. Amar Sethi as Chief Scientific Officer to enhance its scientific strategy and capabilities in drug testing and toxicology [1][5] Company Overview - VivoSim Labs is a pharmaceutical and biotechnology services company focused on testing drugs in three-dimensional human tissue models, specifically for liver and intestine [6] - The company anticipates increased adoption of its human tissue models following FDA's announcement to refine animal testing requirements in favor of non-animal methods [6] Leadership Appointment - Dr. Amar Sethi brings three decades of experience in pharmaceutical drug development, CRO leadership, and diagnostic innovation [2] - His previous roles include leading global clinical programs and developing FDA-qualified biomarker platforms, contributing to significant business growth [4] Strategic Focus - Dr. Sethi will lead initiatives in toxicology, translational models, and bioanalytics, aiming to enhance multi-parametric toxicity prediction using human-relevant systems [3] - The company aims to integrate advanced 3D biology with AI-driven analytics to provide earlier decision-ready insights for sponsors [5] Market Positioning - VivoSim Labs is positioned to be a preferred scientific partner as the industry increasingly adopts 3D NAM systems for drug development [5]